Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Armuzzi

Showing results (221-230 of 320) with videos related to

Pageof 32
Sort By:
Journal of Crohn'S & Colitis|September 13, 2024
Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel DiseaseTommaso Lorenzo Parigi, Luca Massimino, Alfredo Carini, et al.
BMC Gastroenterology|March 28, 2024
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trialsLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Expert Opinion on Biological Therapy|September 15, 2021
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from ItalyMichele Francesco Chiappetta, Anna Viola, Mauro Mastronardi, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 26, 2023
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical RemissionLaura Parisio, Carlo Romano Settanni, Simone Varca, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 19, 2010
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel diseaseMario Cottone, Anna Kohn, Marco Daperno, et al.
Inflammatory Bowel Diseases|April 2, 2019
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With InfliximabAgnese Favale, Sara Onali, Flavio Caprioli, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 26, 2016
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based studyLaurent Peyrin-Biroulet, Gert Van Assche, Andreas Sturm, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2019
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE OpenBruce E Sands, Alessandro Armuzzi, John K Marshall, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 4, 2016
Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort studyGert Van Assche, Laurent Peyrin-Biroulet, Andreas Sturm, et al.
Pageof 32

Showing results (221-230 of 320) with videos related to

Sort By:
Pageof 32
Journal of Crohn'S & Colitis|September 13, 2024
Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel DiseaseTommaso Lorenzo Parigi, Luca Massimino, Alfredo Carini, et al.
BMC Gastroenterology|March 28, 2024
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trialsLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Expert Opinion on Biological Therapy|September 15, 2021
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from ItalyMichele Francesco Chiappetta, Anna Viola, Mauro Mastronardi, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 26, 2023
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical RemissionLaura Parisio, Carlo Romano Settanni, Simone Varca, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 19, 2010
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel diseaseMario Cottone, Anna Kohn, Marco Daperno, et al.
Inflammatory Bowel Diseases|April 2, 2019
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With InfliximabAgnese Favale, Sara Onali, Flavio Caprioli, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 26, 2016
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based studyLaurent Peyrin-Biroulet, Gert Van Assche, Andreas Sturm, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2019
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE OpenBruce E Sands, Alessandro Armuzzi, John K Marshall, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 4, 2016
Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort studyGert Van Assche, Laurent Peyrin-Biroulet, Andreas Sturm, et al.
Pageof 32